多中心回顾性分析晚期胰腺腺泡细胞癌的化疗：含铂和伊立替康方案的潜在疗效。
Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.
机构信息
From the Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa.
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo.
出版信息
Pancreas. 2021 Jan 1;50(1):77-82. doi: 10.1097/MPA.0000000000001718.
OBJECTIVES
The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC).
METHODS
Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument.
RESULTS
The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23-1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15-1.19; P = 0.09) at least once in the treatment course as compared with those who had not.
CONCLUSIONS
Our findings suggested that platinum- and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.
目的
本多中心回顾性研究旨在确定晚期胰腺腺泡细胞癌（PACC）的最佳化疗方案。
方法
纳入了 1996 年至 2013 年间接受化疗的 58 例经组织病理学证实的晚期 PACC 患者。从 16 家日本机构的病历中使用标准化数据收集工具收集了患者的临床特征和治疗效果数据。
结果
最常选择的治疗方案是含吉西他滨、氟嘧啶、铂类和伊立替康的方案。一线化疗患者的总缓解率分别为 7%和 38%，中位总生存期为 13.2 个月。当汇总所有治疗线的数据时，吉西他滨、氟嘧啶、铂类和伊立替康方案的缓解率分别为 7%、18%、40%和 29%。与未接受铂类或伊立替康方案治疗的患者相比，至少接受过一次铂类或伊立替康方案治疗的患者的总生存期有改善趋势（铂类：风险比，0.50；95%置信区间，0.23-1.11；P=0.08；伊立替康：风险比，0.42；95%置信区间，0.15-1.19；P=0.09）。
结论
我们的研究结果表明，含铂类和伊立替康的方案对晚期 PACC 患者具有一定的疗效潜力。
Zotero 插件